Bio-Techne Releases GMP Rock Inhibitor and CHIR 99021 for Stem Cell Therapy

MINNEAPOLIS, Dec. 4, 2018 /PRNewswire/ — Bio-Techne has further added to its cell therapy portfolio by expanding the range of Tocris Bioscience-branded cGMP small molecules to include the commonly used stem cell compounds, Y-27632 (ROCK inhibitor) and CHIR 99021. Y-27632 is a ROCK inhibitor used in stem cell cryopreservation, expansion and differentiation protocols to enhance stem cell survival... Read more

The EORTC Brain Tumor Group and Protagen AG announce their collaboration to investigate the immuno-competence of long-term Glioblastoma survivors

Zurich, Switzerland and Dortmund, Germany – 4 December 2018 – The European Organization for Research and Treatment of Cancer (EORTC) Brain Tumor Group and Protagen AG today announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify autoantibody biomarkers that investigate the immunological profile and immuno-competence of long-term Glioblastoma survivors. Glioblastoma is the most... Read more

Cofactor Genomics to Provide Solid Tumor Immune Profiling for Genocea Biosciences

— Pilot study to evaluate use of Cofactor assay in Genocea’s neoantigen vaccine clinical trial —December 04, 2018 09:00 AM Eastern Standard Time SAN FRANCISCO–(BUSINESS WIRE)–Cofactor Genomics, a clinical RNA sequencing and translational assay developer, today announced a pilot study to evaluate use of Cofactor’s ImmunoPrismTM assay in Genocea Biosciences’ Phase 1/2a clinical trial testing the... Read more

Sartorius and Immunochina Partner to Advance Immunotherapy Development

December 03, 2018 02:00 AM Pacific Standard Time BEIJING–(BUSINESS WIRE)–Sartorius Stedim Biotech (SSB), a leading international supplier of the biopharmaceutical industry, through its China affiliate, and Beijing-based Immunochina Pharmaceuticals, announced today that both parties have entered into a collaboration. Under the terms of the relationship, Immunochina will gain preferred access to SSB’s bioprocess technology platform... Read more

Bio-Rad Quality Controls Now Available for Multiple Abbott Clinical Diagnostics Platforms

Date: 12/03/2018 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced expanded global access of the company’s quality controls across multiple Abbott clinical diagnostics platforms that now includes the Abbott Alinity ci-series instruments. “We are pleased to fulfill this need and offer customers... Read more

QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs

Hilden, Germany, Germantown, Maryland, Fort Myers, Florida, November 30, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer patients. The partnership between QIAGEN and NeoGenomics, a leading provider of... Read more

BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversion

FRANKLIN LAKES, N.J., Nov. 29, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new software application designed to help hospitals and health systems identify drug diversion at the 2018 American Society of Health-System Pharmacists (ASHP) Midyear Meeting. Addiction to prescription narcotics in... Read more

MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018

27 NOV 2018 | DARMSTADT, GERMANY MilliporeSigma’s proxy-CRISPR wins Special Recognition Market Disruptor — Products award Burlington, Massachusetts, November 27, 2018 – MilliporeSigma today announced that it has won two R&D 100 Awards. The 56th annual R&D 100 Awards program, honoring the 100 most innovative and significant technologies introduced in the past year, recognized MilliporeSigma for its BioReliance® Viral and Gene Therapy Assay... Read more

AddLife acquires Austrian Biomedica – international expansion on 13 new markets

26.11.2018 – 14:00 Life science group AddLife is continuing on its growth journey and is now taking an important step in its expansion and internationalisation strategy by acquiring Austrian Biomedica Medizinprodukte GmbH (“Biomedica”). Biomedica, which is the parent company of a group with sales of about EUR 65 million, engages in operations in 13 countries... Read more